To evaluate the safety and efficacy of a 2-weekly cabazitaxel schedule in patients with metastatic castration-resistant prostate cancer (mCRPC). 
Introduction
Prostate cancer is the most common cancer and the third most common cause of cancer death among men in developed countries [1] . Patients with advanced prostate cancer are initially treated with androgen deprivation therapy (ADT), but this treatment is not curative and patients invariably develop metastatic castration-resistant prostate cancer (mCRPC) within a median of 2 years [2, 3] .
Several life-extending therapies are now available for mCRPC, including docetaxel [4] , cabazitaxel [5] , next-generation androgen receptor-targeted agents (abiraterone acetate [6] , enzalutamide [7] ), radium 223 [8] and sipuleucel-T [9] . The standard first-line chemotherapy is docetaxel plus prednisone, which is recommended by many international guidelines [10] [11] [12] . It is associated with improved overall survival (OS), quality of life and pain relief [4] . A meta-analysis of randomized controlled trials also recommends the use of docetaxel in combination with ADT as the standard of care (Level 1 evidence) in patients with newly diagnosed metastatic hormone-sensitive prostate cancer [13] .
Cabazitaxel, a next-generation taxane, was associated with a significant OS benefit in patients with mCRPC who had progressed during or after docetaxel in the TROPIC trial [5] . Prospective studies also suggest that it retains its activity in patients previously treated with next-generation androgen receptor-targeted agents [14] . In these studies, cabazitaxel was given at a dosage of 25 mg/m² every 3 weeks. The main treatment-related toxicities in the TROPIC trial were grade ≥3 neutropenia (82%), febrile neutropenia (8%) and diarrhoea (6%). In the recent phase III PROSELICA trial, cabazitaxel 20 mg/m 2 every 3 weeks was shown to be non-inferior to cabazitaxel 25 [16] .
In a randomized phase III clinical trial, a 2-weekly regimen of docetaxel (50 mg/m 2 on cycle days 1 and 15) was better tolerated than the 3-weekly schedule, with same time to treatment failure but a greater survival benefit [17] . This regimen is recommended by International Society of Geriatric Oncology (SIOG) guidelines for frail patients with mCRPC [18] .
Based on these findings, we hypothesized that a 2-weekly schedule of cabazitaxel would be better tolerated than the usual 3-weekly schedule, while retaining its activity; therefore, this prospective study evaluated the safety and efficacy of a 2-weekly cabazitaxel schedule in patients with mCRPC.
Materials and Methods

Patients
Consecutive patients with mCRPC eligible for treatment with cabazitaxel who presented to the European Georges Pompidou Hospital (French institution) from October 2013 to February 2016 were eligible for the study. To be included, patients needed to: have progressed during or after docetaxel treatment; have an Eastern Cooperative Oncology Group performance status (ECOG-PS) of 0-2; and have adequate haematological and hepatic function. The study was conducted in accordance with the principles of Good Clinical Practice and the Declaration of Helsinki, and was approved by an independent ethics committee (number 2016DAP12).
Study Design and Treatment
In this single-centre, prospective pilot study, patients with mCRPC received cabazitaxel 16 mg/m 2 infused over the course of 1 h on days 1 and 15 of a 4-week cycle. All patients also received prophylactic G-CSF (for 3 days on days 3 to 5 and days 17 to 19) according to ASCO [19] and EORTC [20] guidelines, and prednisone 10 mg/day continuously. Treatment was administered for a maximum of six cycles or until disease progression, unacceptable toxicity or death. The dose of cabazitaxel could be reduced or delayed in the presence of unacceptable toxicity.
Follow-Up
Patients were followed during treatment and until progression or death. The database was closed in February 2017. Data on toxicity (clinical and biological) and PSA concentration were collected before each cabazitaxel administration and every 3 months after the end of the treatment.
Statistical Analysis
At our institution, the background rate of grade ≥3 neutropenia measured at nadir in patients treated with 3-weekly cabazitaxel 25 mg/m 2 plus prophylactic G-CSF was 32%. We estimated that 40 patients would be sufficient to show a reduction of 20% in the incidence of grade ≥3 neutropenia with 2-weekly cabazitaxel 16 mg/m 2 plus prophylactic G-CSF with a power of 85% and a two-sided significance level of 0.05.
The primary endpoint was the percentage of patients with grade ≥3 toxicities associated with cabazitaxel 16 mg/m 2 2-weekly, as per the National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0. Treatment discontinuations for unacceptable toxicity were recorded. The secondary endpoint was cabazitaxel efficacy, including PSA response rate (confirmed reduction in serum PSA concentration of ≥50% and ≥30% from baseline). Biological progression-free survival (PFS) was defined as time to PSA progression (an increase of ≥25% over nadir PSA concentration) or death. Radiological and/or clinical PFS was defined as time to Response Evaluation Criteria In Solid Tumors (RECIST) progression (using RECIST criteria 1.0) and/or clinical progression (worsening of ECOG-PS and/or worsening of pain) or death. OS was calculated from the first ADT initiation, from the first life-extending therapy in the mCRPC setting and from the first cycle of cabazitaxel. The Kaplan-Meier method was used for time to PSA progression, time to clinical or radiological progression, time to any progression and OS.
Results
Patients
From October 2013 to February 2016, 43 patients received 2-weekly cabazitaxel. Prostate cancer history, tumour characteristics and treatments received were collected and are shown in Table 1 . The median (range) time from diagnosis to cabazitaxel initiation was 8.1 (0.8-22.2) years. All patients were pretreated with docetaxel and 79.1% of patients had received prior abiraterone acetate. Patient clinical and biological characteristics at cabazitaxel initiation are reported in Table 2 .
Treatment and Outcomes
A total of 371 cabazitaxel infusions were given (median [range] 9 [2-13] infusions per patient), i.e. 4.5 cycles of 4 weeks (range 1-6.5). Disease progression was the primary reason for treatment discontinuation (32.6%, n = 14). Sixteen patients (37.2%) had dose reductions after first cabazitaxel administration; the median dose reduction was 12.80 (9.49-14.21) mg/m 2 . Eleven patients (25.6%) had dose delays after first administration. Forty-two patients (97.7%) received G-CSF primary prophylaxis and one received G-CSF secondary prophylaxis because of lack of therapeutic observance. The median (range) follow-up duration was 12.9 (2.1-36) months. No patients were lost to follow-up.
Safety
Grade ≥3 toxicities were reported in 15 patients (34.9%; Table 3 ). The main grade ≥3 events were asthenia, neutropenia and thrombocytopenia. Two patients (4.7%) were treated for febrile neutropenia. One patient died from febrile neutropenia associated with thrombocytopenia and anaemia; one possible reason for this was that the second cabazitaxel injection was given too early (on day 11 vs day 15). Adverse events required treatment discontinuation in six patients (14.0%); these included grade 3 asthenia (n = 2), grade 3 thrombocytopenia (n = 1), grade 3 diarrhoea (n = 1), grade 3 haematuria (n =1 ), and febrile neutropenia leading to death (n = 1).
Efficacy
More than half of the patients (n = 25, 58.1%) had a biological, radiological and/or clinical response (Table 4) , nine patients (20.9%) had disease stabilization and nine (20.9%) had immediate PSA progression. Maximum PSA declines are shown in Fig. 1 . PFS data are reported in Table 4 , and Kaplan-Meier curves are shown in Fig. 2 . The median OS from the first administration of cabazitaxel was 15.2 months (95% CI 9.9-19.1; Fig. 2D ). The median OS was 6.5 years (95% CI 5.1-9.5) from initiation of first ADT and 3.4 years from initiation of first docetaxel dose (95% CI 2.2-4.4).
Discussion
The results of this prospective study suggest that a 2-weekly regimen of cabazitaxel is feasible and has a manageable EBRT, external beam radiation therapy. Creatinine clearance <60 mL/min. toxicity profile in docetaxel-and abiraterone acetatepretreated patients with mCRPC, and seemed to retain adequate activity.
These findings are similar to those of another recent study in which use of biweekly cabazitaxel after docetaxel in patients with mCRPC was reported to be well tolerated [21] . Regarding haematological toxicities, the rate of grade ≥3 neutropenia measured at nadir with cabazitaxel 16 mg/m 2 plus prophylactic G-CSF (11.6%) was, as expected, much lower than in the TROPIC trial (82%) [5] [15] , where prophylactic G-CSF during cycle 1 was not allowed; however, it is also lower than in the European compassionate-use and expanded-access programmes (CUP/ EAP) (17%) [16] where prophylactic G-CSF was given in a majority of patients, although neutropenia may not have been captured at nadir in all patients. Indeed, in our institution, cabazitaxel 25 mg/m 2 every 3 weeks is routinely given with prophylactic G-CSF and the rate of grade ≥3 neutropenia at nadir appears higher (32%; S. Oudard, unpublished data). The rates of grade ≥3 thrombocytopenia (9.3%) and asthenia (16.3%) were slightly higher in the present study compared with TROPIC (4% and 5%, respectively), PROSELICA (2.6-4.2% and 2.6-3.7%, respectively) and the European CUP/EAP (1.1% and 2.9%, respectively) but similar to a post hoc analysis of TROPIC limited to French centres [22] . The incidence of grade ≥3 diarrhoea in the present study (7%) was similar to the rate in the TROPIC trial (6%) but slightly higher than in the PROSELICA trial (1.4-4%) . Notably, the present study cohort reflected real-life practice and differed from the highly selected populations of the TROPIC and PROSELICA trials. Our patients had a higher rate of prior treatment with next-generation androgen receptor-targeted agents (79.1% vs 0% in TROPIC and 25.6% in PROSELICA), a higher rate of ECOG-PS ≥2 (27.9% vs 7% in TROPIC and 10% in PROSELICA) and were slightly older (median age 70 years vs 68 years in both TROPIC and PROSELICA). High baseline neutrophil-lymphocyte ratio (NLR) was also relatively common in the present study (44%), and there is increasing evidence that this may be associated with poor outcome [23] . Lastly, five patients had pre-existing grade ≥1 thrombocytopenia at cabazitaxel initiation, reflecting diffuse bone marrow involvement, which may have contributed to the higher rate of grade 3-4 thrombocytopenia in the present study compared with the TROPIC trial.
Two patients out of 43 developed febrile neutropenia, despite prophylactic use of G-CSF starting from the first cabazitaxel cycle. One of these occurred because of a dosing error (the second dose of cabazitaxel in one cycle was given earlier than planned). Use of prophylactic G-CSF has been shown to decrease the rate of grade 3-4 neutropenia and febrile neutropenia in the European CUP/EAP [16] , especially in elderly patients. In addition, SIOG guidelines highly recommend the use of routine G-CSF prophylaxis during administration of a cabazitaxel regimen. G-CSF treatment is widely used in France to prevent chemotherapy adverse events [22] and a recent post hoc analysis of TROPIC suggests that it has no deleterious effect on OS [24] .
The results of our pilot study suggest that the efficacy of 2-weekly cabazitaxel in the third-line setting seems to be comparable to that reported with the 25-mg/m 2 dose in the TROPIC and PROSELICA trials. The ≥50% PSA response rate was 39.5% in the present study, very close to the 39.2% observed in TROPIC trial and 42.5% in the PROSELICA trial. The median PFS (3.7 vs 2.8 vs 3.5 months) and OS (15.0 vs 15.1 vs 14.5 months) were also similar in the three studies. Our results are consistent with a recent multicentre retrospective study that reported an OS time of 13.3 months and a ≥50% PSA response rate of 41.3% with 3-weekly cabazitaxel [25] . By contrast, the efficacy of cabazitaxel in the present study seems slightly better than that reported with cabazitaxel in the third-line setting (OS 10.9 months and ≥50% PSA decrease in 35%) [26] . The latter study did not report toxicity outcomes but included patients who had a worse ECOG-PS and a higher PSA level than our patients, a population who might do better on a 2-weekly cabazitaxel regimen. A phase III study on these two different cabazitaxel schedules is necessary to fully define the comparative efficacy and tolerability of the two regimens. Two-weekly administration of taxanes might be a good approach to improve outcomes of patients who may not be fit enough to receive the standard regimen [17] and is indeed recommended by SIOG guidelines for frail elderly patients with mCRPC [18] . It facilitates a significant reduction in the incidence of grade ≥3 neutropenia and potential associated neutropenic complications.
The patients included in the present pilot study were representative of those encountered in clinical practice, and this is a strength of the trial. According to new SIOG recommendations [27] , patient age should not be a barrier to administration of chemotherapy; instead the choice of treatment should be based on general health and patient preference. The generalizability of our results is limited, however, by the design of the study (the inclusion of patients from a single centre, lack of randomization and relatively small patient numbers).
In conclusion, the results of the present pilot phase II trial suggest that 2-weekly cabazitaxel given with prophylactic G-CSF may be an interesting therapeutic option for mCRPC, especially in heavily pretreated patients who may be too frail to receive the standard 3-weekly cabazitaxel regimen. These preliminary findings need to be confirmed in a large prospective phase III trial of 2-weekly cabazitaxel compared with the standard 3-weekly regimen. 
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